Quest Diagnostics Incorporated DGX
236.32
(0.27)
(0.11%)
as of 25 Sep
- Market cap
- $26.2B
- P/E
- 24.8×
Follow DGX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Quest Diagnostics Incorporated (DGX) Net margin
Quest Diagnostics Incorporated's net margin over the twelve months to 30 June 2026 was 9.15%, up 0.2 percentage points from fiscal 2025 (8.95%). Over the past ten years it has ranged from 8.77% (fiscal 2024) to 18.4% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Diagnostics & Research industry median of −6.37% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 8.95% | 0.18 |
| FY2024 | 8.77% | (0.42) |
| FY2023 | 9.19% | (0.34) |
| FY2022 | 9.53% | (8.90) |
| FY2021 | 18.4% | 3.33 |
| FY2020 | 15.1% | 3.99 |
| FY2019 | 11.1% | 1.34 |
| FY2018 | 9.77% | (0.66) |
| FY2017 | 10.4% | 1.53 |
| FY2016 | 8.90% | (0.52) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 10.5% | 1.82 |
| Mar 2026 | 8.70% | 0.11 |
| Dec 2025 | 8.59% | (0.11) |
| Sep 2025 | 8.70% | (1.51) |
| 42 more quarters | Free account |
Against its own ten years
Low 8.77%
High 18.4%
Ten-year median
9.53%
Current reading's percentile
27
Net margin against peers
| Company | Net margin |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 25.0% |
| MTD Mettler-Toledo International, Inc. compare | 21.9% |
| ILMN Illumina, Inc. compare | 18.4% |
| MEDP Medpace Holdings, Inc. compare | 17.7% |
| DGX Quest Diagnostics Incorporated | 9.15% |
| RVTY Revvity Inc. compare | 8.16% |
| LH Labcorp Holdings Inc. compare | 6.99% |
| WAT Waters Corporation compare | 3.59% |
| GH Guardant Health, Inc. compare | −38.3% |
| Diagnostics & Research industry median | −6.37% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on DGX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement